Fig. 1
Expression and activity of SLC1A1 and SLC1A3 is altered in SN38- and oxaliplatin-resistant CRC lines. a Relative mRNA levels of SLC1A1 and SLC1A3 in parental (PAR), SN38- and oxaliplatin-resistant HCT116 and LoVo cells, determined by qPCR analysis. b Protein levels of SLC1A1 in parental, SN38- and oxaliplatin-resistant HCT116 and LoVo cells relative to that in their parental counterparts. Representative Western blots (p150 serves as a loading control) and densitometric quantification of the Western blot data are shown. The qPCR and Western blot data represent 3 independent experiments per condition. *) p < 0.05, **) p < 0.01, and ***) p < 0.001, compared to parental cells by one-way ANOVA and Dunnett post-test. c-d [3H]-D-Asp uptake level in parental (PAR), SN38- and oxaliplatin-resistant HCT116 and LoVo cells in the [3H]-D-Asp uptake assay. Concentration-inhibition curves for L-Glutamate (L-Glu), DL-TBOA (TBOA) and UCPH-101 in parental, SN38- and oxaliplatin-resistant HCT116 and LoVo cells, respectively. Values are based on four experiments each performed in duplicate